BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030

The global BPH surgical treatment market is valued at an estimated 12.62 billion in 2024 and is projected to reach USD 17.19 billion by 2030, at a CAGR of 5.3% during the forecast period. The growing elderly male population is leading to the cause of BPH patients globally. Therefore, BPH is related to age, and aging is known as a risk factor for BPH. Approximately 50% of men over the age of 50 and around 80% of men over the age of 70 are under the influence of BPH.

In 2023, the alpha-blockers segment accounted for the largest share of the BPH surgical treatment market, by drug type.

Alpha-blockers, 5-alpha reductase inhibitors, and other drug types make up the drug-type-based segments of the BPH surgical treatment market. Market share for BPH surgical treatment was highest in the Alpha-blockers in 2023. This is mainly due to the Alpha-blockers being recommended as first-line treatment for BPH. α-blockers relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction.

“The home care settings segment is projected to witness the highest growth rate in BPH surgical treatment market, by the end-user, during the forecast period.”

Based on end users, the BPH surgical treatment market is segmented into hospitals, ambulatory surgery centers & clinics, and home care settings. The driving factors that force home care settings to BPH surgical treatment is that the patients prefer taking medicine over surgery in most cases, which has supported the growth of this segment. Also, patients avoid surgical or minimally invasive procedures (e.g., TURP, laser therapy) due to potential complications, discomfort, or recovery time.

“The Asia Pacific region is projected to witness highest growth rate in the BPH surgical treatment market during the forecast period”

The global BPH surgical treatment market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Throughout the forecast period, the BPH surgical treatment market is expected to grow at the fastest rate in the Asia Pacific region. The demand for BPH surgical treatment in the APAC is mainly driven by the growing geriatric population, the increasing GDP of Asian countries, the rising healthcare expenditure in the APAC countries, and growing public awareness.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 – 50%, Tier 2 - 30%, and Tier 3 - 20%

By Designation: C-level - 25%, D-level - 20%, and Others - 55%

By Region: North America – 35%, Europe – 32%, Asia Pacific – 21%, Latin America – 8%, Middle East & Africa – 1%, and the GCC Countries – 3%

Lists of Companies Profiled in the Report:

GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark), IPG Photonics Corporation (Russia), ProstaLund AB (Sweden), Karl Storz Se & Co. KG (Germany), Richard Wolf Gmbh (Germany), and Quanta System (Italy), Asclepion Laser Technologies GmbH (Germany), Cook Medical (US), SRS Medical (US), Pnn Medical A/S (Denmark), Allium Ltd. (Israel), Urologix, LLC (US), and Medifocus, Inc. (Canada).

Research Coverage:

In this report, the BPH surgical treatment market has been categorized based on drug type (alpha-blockers, 5-alpha reductase inhibitors, and other drug types), type (Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezūm Procedure, Robot-assisted waterjet ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic arterial embolization (PAE) and others) end user (hospitals, ASCs & clinics, and home care settings), therapy (monotherapy and combination drug therapy), and region (Europe, Middle East & Africa, North America, Latin America, Asia Pacific, and the GCC Countries).

Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the BPH surgical treatment market's expansion is included in detail in this study. An exhaustive study of the key players in the cochlear implants market has been done to provide insights into their business profiles, products offered, noteworthy strategies, product launches, and approvals, and other recent activities pertaining to the market.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall BPH surgical treatment market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restraints.

The report provides insights on the following pointers:

Analysis of key drivers: (Expanding aging population and increasing prevalence of BPH, Rising cases of obesity in males, and Growing preference for minimally invasive surgeries), restraints (High cost of cochlear implants and associated surgeries and surgical risks, procedural complications, and long post-surgery rehabilitation), opportunities (Side effects associated with BPH medications and High cost of BPH surgical treatment), and challenges (Shortage of skilled professionals, Low awareness regarding prostate health and Product recalls) influencing the growth of the in BPH surgical treatment market.

Market Development: Comprehensive information about lucrative markets – the report analyses the BPH surgical treatment market across varied regions.

Product Development/Innovation: Comprehensive information about product development and new technologies – the report analyses the BPH surgical treatment market.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the BPH surgical treatment market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark) and IPG Photonics Corporation (Russia) in the BPH surgical treatment market strategies. Show more